"alt_sample_name"	"unique_patient_ID"	"sample_type"	"histological_type"	"primarysite"	"arrayedsite"	"summarygrade"	"summarystage"	"tumorstage"	"substage"	"grade"	"age_at_initial_pathologic_diagnosis"	"pltx"	"tax"	"neo"	"days_to_tumor_recurrence"	"recurrence_status"	"days_to_death"	"vital_status"	"os_binary"	"relapse_binary"	"site_of_tumor_first_recurrence"	"primary_therapy_outcome_success"	"debulking"	"percent_normal_cells"	"percent_stromal_cells"	"percent_tumor_cells"	"batch"	"uncurated_author_metadata"
"GSM461348"	317	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	4500	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 317///geo_accession: GSM461348///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 150 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 317///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461348/GSM461348.CEL.gz///data_row_count: 54675"
"GSM461349"	332	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	210	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 332///geo_accession: GSM461349///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 7///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 332///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461349/GSM461349.CEL.gz///data_row_count: 54675"
"GSM461350"	349	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	4320	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 349///geo_accession: GSM461350///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 144 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 349///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461350/GSM461350.CEL.gz///data_row_count: 54675"
"GSM461351"	351	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	4260	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 351///geo_accession: GSM461351///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 142 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 351///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461351/GSM461351.CEL.gz///data_row_count: 54675"
"GSM461352"	386	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	2850	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 386///geo_accession: GSM461352///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 95///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 386///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461352/GSM461352.CEL.gz///data_row_count: 54675"
"GSM461353"	388	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	3960	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 388///geo_accession: GSM461353///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 132 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 388///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461353/GSM461353.CEL.gz///data_row_count: 54675"
"GSM461354"	389	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	390	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 389///geo_accession: GSM461354///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 13///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 389///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461354/GSM461354.CEL.gz///data_row_count: 54675"
"GSM461355"	402	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	240	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 402///geo_accession: GSM461355///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 8///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 402///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461355/GSM461355.CEL.gz///data_row_count: 54675"
"GSM461356"	410	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	4500	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 410///geo_accession: GSM461356///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 150 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 410///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461356/GSM461356.CEL.gz///data_row_count: 54675"
"GSM461357"	412	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	3390	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 412///geo_accession: GSM461357///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 113///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 412///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461357/GSM461357.CEL.gz///data_row_count: 54675"
"GSM461358"	434	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	2160	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 434///geo_accession: GSM461358///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 72///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 434///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461358/GSM461358.CEL.gz///data_row_count: 54675"
"GSM461359"	467	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	330	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 467///geo_accession: GSM461359///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 467///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461359/GSM461359.CEL.gz///data_row_count: 54675"
"GSM461360"	629	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1500	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 629///geo_accession: GSM461360///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 50 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 629///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461360/GSM461360.CEL.gz///data_row_count: 54675"
"GSM461361"	702	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	390	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 702///geo_accession: GSM461361///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 13///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 702///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461361/GSM461361.CEL.gz///data_row_count: 54675"
"GSM461362"	714	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	240	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 714///geo_accession: GSM461362///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 8///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 714///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461362/GSM461362.CEL.gz///data_row_count: 54675"
"GSM461363"	765	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	360	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 765///geo_accession: GSM461363///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 12///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 765///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461363/GSM461363.CEL.gz///data_row_count: 54675"
"GSM461364"	780	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	330	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 780///geo_accession: GSM461364///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 780///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461364/GSM461364.CEL.gz///data_row_count: 54675"
"GSM461365"	799	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	150	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 799///geo_accession: GSM461365///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 5///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 799///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461365/GSM461365.CEL.gz///data_row_count: 54675"
"GSM461366"	872	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	270	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Ovarian Tumor, 872///geo_accession: GSM461366///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 9///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 872///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461366/GSM461366.CEL.gz///data_row_count: 54675"
"GSM461367"	1231	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	450	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 1231///geo_accession: GSM461367///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1231///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461367/GSM461367.CEL.gz///data_row_count: 54675"
"GSM461368"	1562	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	570	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 1562///geo_accession: GSM461368///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 19 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1562///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461368/GSM461368.CEL.gz///data_row_count: 54675"
"GSM461369"	1660	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	450	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 1660///geo_accession: GSM461369///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1660///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461369/GSM461369.CEL.gz///data_row_count: 54675"
"GSM461370"	662	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	690	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 662///geo_accession: GSM461370///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 23///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 662///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461370/GSM461370.CEL.gz///data_row_count: 54675"
"GSM461371"	800	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1080	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 800///geo_accession: GSM461371///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 36///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 800///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461371/GSM461371.CEL.gz///data_row_count: 54675"
"GSM461372"	934	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1080	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-08"	"title: Ovarian Tumor, 934///geo_accession: GSM461372///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 36 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 934///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461372/GSM461372.CEL.gz///data_row_count: 54675"
"GSM461373"	324	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1770	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 324///geo_accession: GSM461373///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 59///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 324///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461373/GSM461373.CEL.gz///data_row_count: 54675"
"GSM461374"	377	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	360	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 377///geo_accession: GSM461374///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 12///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 377///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461374/GSM461374.CEL.gz///data_row_count: 54675"
"GSM461375"	380	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1710	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 380///geo_accession: GSM461375///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 57///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 380///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461375/GSM461375.CEL.gz///data_row_count: 54675"
"GSM461376"	396	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	630	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 396///geo_accession: GSM461376///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 396///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461376/GSM461376.CEL.gz///data_row_count: 54675"
"GSM461377"	443	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	3330	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 443///geo_accession: GSM461377///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 111///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 443///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461377/GSM461377.CEL.gz///data_row_count: 54675"
"GSM461378"	744	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	420	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Ovarian Tumor, 744///geo_accession: GSM461378///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 14///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 744///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461378/GSM461378.CEL.gz///data_row_count: 54675"
"GSM461379"	312	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1440	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 312///geo_accession: GSM461379///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 48///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 312///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461379/GSM461379.CEL.gz///data_row_count: 54675"
"GSM461380"	321	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1350	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 321///geo_accession: GSM461380///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 45///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 321///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461380/GSM461380.CEL.gz///data_row_count: 54675"
"GSM461381"	367	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	480	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 367///geo_accession: GSM461381///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 367///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461381/GSM461381.CEL.gz///data_row_count: 54675"
"GSM461382"	394	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	480	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 394///geo_accession: GSM461382///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 394///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461382/GSM461382.CEL.gz///data_row_count: 54675"
"GSM461383"	477	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	630	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 477///geo_accession: GSM461383///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 477///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461383/GSM461383.CEL.gz///data_row_count: 54675"
"GSM461384"	656	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	750	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 656///geo_accession: GSM461384///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 25///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 656///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461384/GSM461384.CEL.gz///data_row_count: 54675"
"GSM461385"	694	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	990	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 694///geo_accession: GSM461385///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 33///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 694///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461385/GSM461385.CEL.gz///data_row_count: 54675"
"GSM461386"	715	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	990	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 715///geo_accession: GSM461386///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 33///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 715///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461386/GSM461386.CEL.gz///data_row_count: 54675"
"GSM461387"	786	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1440	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 786///geo_accession: GSM461387///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 48 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 786///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461387/GSM461387.CEL.gz///data_row_count: 54675"
"GSM461388"	794	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	450	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 794///geo_accession: GSM461388///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 15///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 794///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461388/GSM461388.CEL.gz///data_row_count: 54675"
"GSM461389"	970	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	540	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-07-20"	"title: Ovarian Tumor, 970///geo_accession: GSM461389///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 18///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 970///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461389/GSM461389.CEL.gz///data_row_count: 54675"
"GSM461390"	1109	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1020	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 1109///geo_accession: GSM461390///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 34 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1109///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461390/GSM461390.CEL.gz///data_row_count: 54675"
"GSM461391"	1214	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	510	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 1214///geo_accession: GSM461391///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 17///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1214///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461391/GSM461391.CEL.gz///data_row_count: 54675"
"GSM461392"	345	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	540	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 345///geo_accession: GSM461392///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 18///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 345///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461392/GSM461392.CEL.gz///data_row_count: 54675"
"GSM461393"	358	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	630	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 358///geo_accession: GSM461393///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 358///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461393/GSM461393.CEL.gz///data_row_count: 54675"
"GSM461394"	461	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	960	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 461///geo_accession: GSM461394///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 32///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 461///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461394/GSM461394.CEL.gz///data_row_count: 54675"
"GSM461395"	486	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	630	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 486///geo_accession: GSM461395///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 21///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 486///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461395/GSM461395.CEL.gz///data_row_count: 54675"
"GSM461396"	631	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	900	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 631///geo_accession: GSM461396///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 30///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 631///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461396/GSM461396.CEL.gz///data_row_count: 54675"
"GSM461397"	692	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	1050	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 692///geo_accession: GSM461397///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 35///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 692///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461397/GSM461397.CEL.gz///data_row_count: 54675"
"GSM461398"	718	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	780	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 718///geo_accession: GSM461398///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 26///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 718///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461398/GSM461398.CEL.gz///data_row_count: 54675"
"GSM461399"	778	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	480	"deceased"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-12"	"title: Ovarian Tumor, 778///geo_accession: GSM461399///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 16///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 778///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461399/GSM461399.CEL.gz///data_row_count: 54675"
"GSM461400"	1993	NA	"tumor"	"ser"	"ov"	NA	"high"	"late"	3	NA	3	NA	NA	NA	NA	NA	NA	330	"living"	NA	NA	NA	NA	"optimal"	0	0	100	"2004-08-13"	"title: Ovarian Tumor, 1993///geo_accession: GSM461400///status: Public on Oct 17 2009///submission_date: Oct 11 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: papillary serous ovarian adenocarcinoma///organism_ch1: Homo sapiens///characteristics_ch1: tissue: papillary serous ovarian adenocarcinoma///characteristics_ch1.1: tumor stage: late///characteristics_ch1.2: tumor grade: high///characteristics_ch1.3: surv data: 11 (A)///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from tumor.///description.1: 1993///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM461nnn/GSM461400/GSM461400.CEL.gz///data_row_count: 54675"
"GSM462643"	2008	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-03-12"	"title: Normal Ovary, 2008///geo_accession: GSM462643///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2008///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462643/GSM462643.CEL.gz///data_row_count: 54675"
"GSM462644"	2061	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Normal Ovary, 2061///geo_accession: GSM462644///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2061///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462644/GSM462644.CEL.gz///data_row_count: 54675"
"GSM462645"	2064	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Normal Ovary, 2064///geo_accession: GSM462645///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2064///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462645/GSM462645.CEL.gz///data_row_count: 54675"
"GSM462646"	2085	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-04-09"	"title: Normal Ovary, 2085///geo_accession: GSM462646///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2085///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462646/GSM462646.CEL.gz///data_row_count: 54675"
"GSM462647"	2225	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2225///geo_accession: GSM462647///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2225///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462647/GSM462647.CEL.gz///data_row_count: 54675"
"GSM462648"	2226	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2226///geo_accession: GSM462648///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2226///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462648/GSM462648.CEL.gz///data_row_count: 54675"
"GSM462649"	2228	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2228///geo_accession: GSM462649///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2228///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462649/GSM462649.CEL.gz///data_row_count: 54675"
"GSM462650"	2230	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2230///geo_accession: GSM462650///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2230///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462650/GSM462650.CEL.gz///data_row_count: 54675"
"GSM462651"	2234	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2234///geo_accession: GSM462651///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2234///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462651/GSM462651.CEL.gz///data_row_count: 54675"
"GSM462652"	2237	NA	"healthy"	NA	"ov"	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	"optimal"	0	0	100	"2004-09-30"	"title: Normal Ovary, 2237///geo_accession: GSM462652///status: Public on Oct 17 2009///submission_date: Oct 16 2009///last_update_date: Jan 19 2011///type: RNA///channel_count: 1///source_name_ch1: normal ovarian surface epithelium (OSE)///organism_ch1: Homo sapiens///characteristics_ch1: tissue: ovarian surface epithelium (OSE)///characteristics_ch1.1: ///characteristics_ch1.2: ///characteristics_ch1.3: ///treatment_protocol_ch1: All specimens were subjected to laser-based microdissection and analyzed as pure, microdissected epithelial cell populations.///molecule_ch1: total RNA///extract_protocol_ch1: RNeasy Micro Kit according to the manufacturers protocol (Qiagen Inc., Valencia, CA).///label_ch1: biotin///label_protocol_ch1: Two rounds of amplification were completed according to standard Affymetrix Two-Cycle Amplification protocol using 25ng of total RNA.///taxid_ch1: 9606///hyb_protocol: A 15 microgram aliquot of amplified biotinylated RNA was hybridized to a Human U133 Plus 2.0 GeneChip array (Affymetrix, Santa Clara, CA).///scan_protocol: Arrays were scanned using the laser confocal GeneChip Scanner 3000 (Affymetrix).///description: Gene expression data from normal ovary.///description.1: HOSE2237///data_processing: Low-level analysis included array normalization and estimation of expression level using an invariant set of probe sets to adjust the overall signal level of the arrays to the same level. Next, a model-based PM-only approach established gene expression levels using dChip software.    A modified semi-supervised method was applied in two stages: (1) supervised dimension reduction by fitting a univariate Cox model that included a jackknifing step to each gene, so only those genes with a consistently large Cox score were included in the signature. Among 200, 100, or 300 probe sets, 200 yielded an optimally sized predictor; (2) In stage 2, the dimensions of the data set were reduced from 200 to 5 by PC analysis. The number of PCs was set at 5 capturing 90% of the expression data. 4 or 6 PCs were investigated to see whether this parameter affected the results. A prediction model was then built using multivariate Cox regression, where independent variables included the first 5 PCs and debulking status.///data_processing.1: Standard leave-one-out validation evaluated the prediction model reserving one sample for testing, and using the remaining 52 patients to establish the prediction model following the method described above. The reserved patient had no contribution to the prediction model yielding 53 separate predicted hazards. Patients were equally divided into low and high-risk groups according to whether their hazard was less or greater than the sample median and were compared by Kaplan Meier analysis with a non-parametric log-rank test.///platform_id: GPL570///contact_name: Michael,,Birrer///contact_email: mbirrer@partners.org///contact_phone: 6177244800///contact_laboratory: Surgical Oncology Research Labs///contact_department: Medicine///contact_institute: MGH///contact_address: 70 Blossom Street///contact_city: Boston///contact_state: MA///contact_zip.postal_code: 2114///contact_country: USA///supplementary_file: ftp://ftp.ncbi.nih.gov/pub/geo/DATA/supplementary/samples/GSM462nnn/GSM462652/GSM462652.CEL.gz///data_row_count: 54675"
